Clinical Trial Update: Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and immunogenicity of CHP-HER2 and CHP-NY-ESO-1 protein vaccines with OK-432 in patients with antigen-expressing cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esophageal Cancer
• Lung Cancer
• Ovarian Cancer
• Stomach Cancer

Drugs mentioned

• CHP-HER2 (Chaperone protein complex targeting HER2)
• CHP-NY-ESO-1 (Chaperone protein complex presenting NY-ESO-1 antigen)
• OK-432 (Streptococcal pyrogenic exotoxin-based immunotherapy (picibanil))

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Esophageal Cancer, Lung Cancer | Phase 1 | Status: COMPLETED